In this retrospective and multicenter study, we identified a small group of high-grade glioma patients, with immunohistochemical loss of mismatch repair protein expression: 12% of screened patients reported a “partial” or “total” loss of expression of one or more MMR complex proteins (MSH2, MSH6, MLH1, and PMS2). This evidence concerns the gene MSH2 and central nervous system cancer.